HRTX - Heron Therapeutics: Zynrelef Potentially Eases Shareholder Pain

2024-04-16 16:24:08 ET

Summary

• HRTX has received approval for its supplemental New Drug Application for Zynrelef, allowing its use in more surgical procedures.
• The company has partnered with Crosslink Life Sciences to promote Zynrelef, which could further drive sales growth.
• The availability of a vial access needle form of Zynrelef might not come until late 2024, but offers an additional milestone for Zynrelef's expansion.

Heron Therapeutics ( HRTX ) has seen a positive start to 2024, with approval of the company's supplemental New Drug Application (sNDA) for Zynrelef allowing the drug to be used in more surgical procedures. I wrote about HRTX in late December 2023, rating the company a buy based on the valuation and the potential of Zynrelef sNDA being approved. This article looks at how Zynrelef can continue to grow in 2024 and also analyzes March's Q4'23 earnings....

For further details see: